Long-term follow-up after RFA with or without prior EMR for early Barrett's neoplasia

Long-term follow-up after RFA with or without prior EMR for early Barrett's neoplasia - 5-year FU after RFA

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON36820

Enrollment

Registered

2011-10-26

Start date

2011-06-10

Completion date

Unknown

Last updated

2024-05-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

(early) esophageal cancer Barrett's esophagus

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: - All eligible patients treated with RFA in the AMC-I/AMC-II/AMC-IV/EURO-I study (resp. MEC05/082 and MEC06/011, MEC 06/184, MEC 06/189), who are now being followed-up endoscopically in the AMC or referral centre in the Netherlands - Written informed consent

Exclusion criteria

Exclusion criteria: - No justification for further follow-up due to (unrelated) comorbidity

Design outcomes

Primary

Measure	Time frame
- Rate of complete histological remission of dysplasia and cancer - Rate of complete endoscopic and histological eradication of IM (including biopsies obtained from neosquamous mucosa)	—

Secondary

Measure	Time frame
- Prevalence of subsquamous IM in neosquamous biopsies and ER-specimens - Prevalence of IM below the Neo Z-line during 5-year follow-up visits - Adverse events	—

Countries

Netherlands

Outcome results